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Abstract
Since the landmark Institute of Medicine report brought patient safety to the forefront of
public concern, there has been intense effort to reduce medication errors in the hospital
setting. One such method, medication reconciliation during transitions in care, is now
standard practice. While many studies have explored contributory factors and
consequences of medication reconciliation errors at hospital admission and hospital
discharge, the role of therapeutic interchange, or the substitution of a chemically different
but therapeutically equivalent drug for the one originally prescribed, on patients’
medication regimens has not been adequately investigated. In fact, no study has examined
the extent to which therapeutic interchange is employed in the hospital and the impact it
has on unintentional medication reconciliation errors.
We analyzed data from a prospective, observational cohort study of patients 65 years or
older admitted to a tertiary care hospital for acute coronary syndrome, heart failure, or
pneumonia between May 2009 and April 2010 who were discharged home. We examined
patients’ medications from six commonly interchanged drug classes (ACE inhibitors,
ARBs, H2 blockers, inhaled corticosteroids, PPIs, and statins) and measured the
frequency of therapeutic interchange at hospital admission, the rate of suspected errors
associated with therapeutic interchange at admission and at discharge, and the role of
therapeutic interchange on drug changes at discharge.
We analyzed 555 admission medications taken by 303 patients that were within the six
drug classes of interest. Of these, 244 (44.0%) were therapeutically interchanged during
hospitalization while the remaining medications were continued or held. We identified 78
(32.0%) therapeutically interchanged medications with suspected errors made at time of
interchange. At discharge, a total of 41 (7.4%) of the 555 medications of interest had a
suspected medication reconciliation error at discharge. 28 of these were medications that
were therapeutically interchanged at admission, giving a relative risk of suspected error
of 2.75 (95% CI 1.45-5.19) compared to medications that were not interchanged. 28 of
the 244 therapeutically interchanged medications (11.5%), as compared to 8 of the 311
non-therapeutically interchanged drugs (2.6%), were switched at discharge to a different
medication within the same drug class as the patient’s original home medication (RR
4.46, 95% CI 2.07-9.61).
Therapeutic interchange during hospitalization is a common practice associated with a
significant number of potential errors at admission and at discharge, creating a risk for
patient misunderstanding and adverse drug events. In light of these findings, methods for
safely practicing therapeutic interchange should be developed to improve patient safety.
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Introduction
Transitions in Care
Since the Institute of Medicine’s 1999 landmark report, “To Err is Human: Building a
Safer Health System” brought patient safety and medical errors to the forefront of public
concern, much research has focused on quality improvement in the inpatient and
outpatient health care settings (1). Concurrently, patient safety advocates have
increasingly identified transitions in care between these settings as an important source of
medical error (2). Transitional care has been defined as “a set of actions designed to
ensure the coordination and continuity of health care as patients transfer between
different locations or different levels of care within the same location” (3). Ideally,
transitions occur in a coordinated, transparent fashion based on comprehensive plans of
care. However, due to the often urgent and unpredictable nature of care transfers, the
medical complexity of patients being transferred, and the necessity of clear, timely, and
accurate communication, transitions in care are periods of heightened vulnerability for
patients (4). The increasing specialization of physicians as well as the restriction of their
practices to specific phases of care (e.g. only hospital-based or ambulatory-based) can
further fragment care (4). In fact, in only one such care transition, discharge following
hospitalization, nearly half of patients may suffer from a medical error or adverse event
(5).
Breakdown in care transitions may occur for many different reasons. These include poor
communication of essential information between healthcare professionals, failure to
complete follow-up care, too much time between follow-up care, lack of transportation,
and incomplete preparation and education of the patient and/or family. One of the most
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significant contributors to transitional care-related adverse events is medication errors
(3).

Medication Reconciliation
Medication errors are one of the most common types of error affecting patient safety and
broadly include any failure in treatment by medications that leads to real or potential
harm to the patient (6). Preventable adverse drug events are associated with up to one in
five healthcare-related injuries or deaths (7). Significantly, nearly half of these errors
occur during transitions in care (8). Medication errors during these transfers are typically
due to incomplete or incorrect transmission of information. The process of obtaining an
accurate patient medication list and transmitting it to the next phase of care is
complicated by the fact that there is often no consistent location for keeping this
information, no integration of medication history across settings, and no standardized
method for collecting the data (8). As such, medication reconciliation, a formal process of
identifying the most accurate, current patient medication list and correcting unintended
discrepancies, is a current patient safety focus aimed at reducing medication errors during
transitions of care. International organizations such as the World Health Organization and
Institute for Healthcare Improvement have widely endorsed medication reconciliation in
the past decade, and the accrediting bodies The Joint Commission and Accreditation
Canada mandate this process (9). Medication reconciliation is now standard practice
during hospital admission and discharge as well as at other points of transfer. For the
purposes of this thesis, the discussion of medication reconciliation will center on
transitions related to hospital-based care, namely hospital admission and hospital
discharge.
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Medication reconciliation has been consistently shown to reduce errors and adverse drug
events (ADEs). For example, Pronovost and colleagues employed a medication
reconciliation tool in the intensive care unit setting of an academic medical center, which
required nurses to reconcile prehospital, ICU-admission, and ICU-discharge medications.
They found that prior to implementation, 94% of ICU patients had at least one
medication error; 24 weeks afterward, none did (7). At another academic center, use of an
electronic documentation tool led to a reduction in discharge medication errors from 90%
to 47% on a surgical unit and from 57% to 33% on a medical unit (10). Vira and
colleagues showed that pharmacist-led reconciliation in a community hospital was able to
detect and prevent 75% of clinically important errors (11). One systematic review found
that 7 of 8 studies demonstrated statistically significant decreases in potential ADEs or
ADEs (12).
However, while nearly all medication reconciliation interventions show reductions in
medication discrepancies and adverse drug events, the effect of these studies on health
care utilization is less clear. Mueller et al. (2012) identified decreases in post-discharge
health care utilization in only 2 of 8 studies, and the two that showed improvement
required intensive pharmacy participation during and after hospitalization (12). Similarly,
in another systematic review, Kwan et al. (2013) found that medication reconciliation is
unlikely to affect 30-day readmission rates or emergency department visits unless
coupled with additional care coordination interventions (9). Thus, while medication
reconciliation is able to detect many errors and may avoid ADEs and potential poor
outcomes, it may not be sufficient to decrease health care utilization.
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Of note, despite the national implementation of medication reconciliation processes
around transitions in care, there is no single standardized method of performing
medication reconciliation, and many different approaches have been shown to be helpful
in improving accuracy. Hospital-based medication reconciliation practices can occur at
multiple times and be completed by various healthcare professionals in many formats
(12). Medication reconciliation typically occurs at admission and discharge but also may
be performed in the emergency department, during hospitalization, and after discharge.
Doctors, nurses, pharmacists, technicians, and/or students can perform reconciliation.
Information gathering comes from sources such as the patient, caregivers, previous or
outside hospital records, outpatient physician records, outpatient pharmacies, and
inpatient progress notes and care teams. Many studies have developed paper and
electronic tools and protocols to assist in medication documentation, and it is unclear
which of these methods is superior (12).
Because of the complex nature of hospital-based medication reconciliation, even
effective medication reconciliation practices are prone to errors. The following is a
discussion of the types, reasons, and frequency of medication reconciliation errors at
hospital admission and hospital discharge.

Medication Reconciliation Errors at Admission
Obtaining an accurate medication history at the time of hospital admission is an integral
part of patient assessment. First, a thorough medication reconciliation may uncover the
reason for hospitalization, such as an adverse drug event or exacerbation of disease due to
nonadherence to drug therapy (13). Furthermore, errors in acquiring the outpatient
medication regimen may lead to interrupted or inappropriate drug therapy during
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hospitalization and possibly after discharge, which may then cause adverse outcomes
(13). Though the importance of performing a comprehensive medication reconciliation at
admission is well understood, many barriers exist to obtaining complete and accurate
information.
As noted above, transitions in care are often abrupt and unexpected events in which
patients and healthcare providers may be unprepared for the change in level of care. One
important source of information for gathering medication history is the patient. However,
patient knowledge of his/her medications at transitions in care is frequently unreliable
and incomplete. In one study, only half of patients presenting to the emergency
department were able to give a list of all of their medications, and only 17% brought a
written list or their prescription bottles with them. Fewer than one fourth of patients were
aware of the dosages of their medications (14). In another study, even among patients
asked to keep a written medication list, 56% of patients had information missing
(medication, dose, and/or frequency) from the list, and 94% of the lists had at least one
discrepancy with clinical medical records (15). Because healthcare providers cannot rely
solely on patient accounts of medication use, they must turn to other sources for data
gathering and verification.
Other common sources include family and caregivers, primary care providers, outpatient
pharmacies, and previous hospital records. Collecting this information is time- and laborintensive, and even the most thorough review of data cannot guarantee complete accuracy
of the patient’s outpatient medication regimen. Instead, the goal of medication
reconciliation at hospital admission is to obtain the best possible medication history
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(BPMH) (16). This BPMH list then becomes the gold standard that is used throughout
hospitalization.
The difficulties involved in acquiring the outpatient medication regimen and then
translating them into inpatient medication orders commonly leads to medication errors. In
fact, errors at admission are among the most common type of hospital-based medication
errors, accounting for up to 27% of all inpatient prescribing errors (17-19). In one wellrecognized systematic review of studies describing medication reconciliation errors at
hospital admission, Tam and colleagues summarized that up to 67% of patients
experience at least one medication reconciliation error at admission, with a range of 1067% (17).
Studies classifying errors made in medication reconciliation at admission consistently
show that omission of a home medication is the most common type of error, comprising
approximately half of admission errors (13,17-19). Other errors include commission, or
the inpatient prescription of a drug that was not being taken prior to admission (13-22%
of errors), as well as discrepancies in dose and/or frequency of drug (30-42% of errors)
(17).

Consequences of Medication Reconciliation Errors at Admission
Fortunately, while admission medication reconciliation errors are very common, most of
these discrepancies have no potential for patient harm. Analyses of the clinical
importance of these errors show that between 60-73% of admission discrepancies are
unlikely to cause adverse events (13,18,20). Still, the remainder of medication
reconciliation errors at admission either does cause harm or has the potential to cause
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patient discomfort or clinical deterioration, as judged by the authors of the studies.
Examples of potential adverse drug events caused by admission medication reconciliation
errors include continuation of an NSAID after gastrointestinal hemorrhage or
unintentionally prescribing an increased dose of a sulfonylurea during hospitalization
(13,20).
The majority of investigations examining the clinical consequences of medication errors
at admission are retrospective chart reviews that look for ADEs or potential ADEs that
may occur during hospitalization. The studies almost never investigate events after
hospital discharge. Instead, most discussions of post-discharge ADEs or potential ADEs
focus on medication reconciliation errors made at discharge (see below). There thus may
be utility in studying the effect of admission medication errors on patients after hospital
discharge. For instance, Gleason and colleagues found that 22% of admission errors had
the potential to cause harm during hospitalization but estimated that 59% of the
admission errors could result in a potential ADE if the error was continued beyond
discharge (20). Furthermore, in another study examining both admission and discharge
medication reconciliation errors, one third of all unintentional medication discrepancies
occurred at admission and were carried through discharge, so any potential ADEs
associated with these inconsistencies could be attributed to the admission medication
reconciliation process rather than at discharge (18). Thus, clarifying between postdischarge clinical consequences that originate upon admission versus at discharge may
provide useful outcomes information.

8

Medication Reconciliation Errors at Discharge
The process of medication reconciliation is also essential at hospital discharge and
involves merging the patient’s best possible medication history obtained at admission
with medication changes that occurred during the hospitalization. Hospitalization can
significantly alter a patient’s medication regimen. In response to acute illness, physicians
may hold or discontinue medications, change dosages and frequency of drugs, or start
new formulations. They may also substitute long-acting or oral medications with shortacting or intravenous drugs, respectively. Furthermore, hospital formularies may
necessitate the use of drugs different from preadmission medications (therapeutic
interchange; see below) (21). Then, at discharge, all of these modifications must be
thoughtfully reconciled to create a new outpatient regimen that begins as soon as the
patient leaves the hospital. Temporary inpatient medications must be stopped, outpatient
medications may be restarted, and formulary substitutions should be switched back to
home drugs; the new list should also reflect any additions or modifications made for
clinical reasons (21). The many changes that occur between admission and discharge
often lead to medication reconciliation errors at discharge. In fact, two studies have
shown that half of discharge medication reconciliations contain unexplained
discrepancies, involving up to 16% of all medications prescribed (22,23). Another study
found a more conservative error rate of 24%, involving 5% of medications examined
(24).
As with errors at admission, the most common type of medication reconciliation
discrepancy at discharge is omission of a drug, which accounts for 30-45% of errors
(11,25). Other contributors to discharge discrepancies include changes to dosage and/or
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frequency, duplication of prescriptions, and incomplete prescriptions (11,25). (The
continuation of therapeutic interchange has been cited as a potential source of error but
has not been explicitly addressed; see below.)

Consequences of Medication Reconciliation Errors at Discharge
Overall, more medication reconciliation errors occur at hospital admission compared to at
discharge, but more potential adverse drug events result with discharge. This reflects the
differences between hospitalization, which is often brief and highly monitored, and the
post-discharge outpatient setting, which has much less healthcare provider oversight so
errors may continue for a prolonged period of time (18).
Adverse events related to medications are among the most common undesirable
outcomes post-discharge. Adverse drug events may arise from various factors, including
patient misunderstanding and inadequate discharge planning, but often can be traced back
to medication reconciliation errors. Studies estimate that ADEs occur in 11-31% of
patients within 30 days of hospital discharge (22,26-28). Many of these, up to 60%, are
preventable or amendable (27,28).
These post-discharge ADEs can cause significant morbidity and potentially mortality.
Patients who experience an ADE after discharge not only undergo additional symptoms
or disabilities but also often require additional health care visits and laboratory testing
(27). Approximately 16% of patients are readmitted to the hospital due to ADEs postdischarge (27).
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The Rise of Therapeutic Interchange
The ever-increasing complexity and costs of various pharmacotherapies is a large
contributing factor to our nation’s continued rise in healthcare expenditures (29).
Therapeutic interchange, or the substitution of a chemically different but therapeutically
equivalent drug for the one originally prescribed, is a widely used option that
theoretically allows healthcare systems to provide a safe yet cost-effective method to
control pharmaceutical expenses and pharmacy size without compromising patient care
(30). Therapeutic interchange is typically employed in the hospital setting in which there
is an established formulary but also may occur in the ambulatory setting when patients
are associated with pharmacy benefit programs (31). Hospitals that have implemented
therapeutic interchange have reported savings ranging from less than $10,000 to greater
than $1 million annually (32). Studies examining the economic effects of therapeutic
interchange within individual drug classes in the outpatient environment have also shown
the potential for significant cost savings among patients and healthcare systems (30,3335).
A survey by Schachtner et al. that aimed to characterize the prevalence of inpatient
therapeutic interchange identified the eleven most frequently interchanged medication
classes in 2002: histamine H2-receptor antagonists, proton pump inhibitors, antacids,
quinolones, potassium supplements, first-, second-, and third-generation cephalosporins,
hydroxymethylglutaryl CoA (HMG-CoA) reductase inhibitors, insulin, and
laxatives/stool softeners (32). Over the past three decades, the percentage of hospitals
using therapeutic interchange has increased dramatically from 31% in 1982 to 92% in
2010 (36,37).
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Risks and Benefits of Therapeutic Interchange
Because the exchange of one medication for another may affect patient care and
outcomes, the use of therapeutic interchange has caused significant debate. Critics of
therapeutic interchange have highlighted several concerning factors related to patient
care. Interchanged drugs are typically of the same pharmacologic class, but as they are
chemically different, they may not be clinically equivalent. Differences in
pharmacokinetics and pharmacodynamics such as absorption, therapeutic effect, and side
effect profile may lead to a reduction in effectiveness or increase in side effects (31,38).
The change in medication also opens the door to prescribing errors that may contribute to
adverse drug events (21). Finally, pharmaceutical companies compete with each other
and negotiate with hospital systems and pharmacy benefit programs to have their drugs
included in these formularies, which can greatly affect prescribing practices (39). While
hospitals may achieve cost-savings for their formularies, the medications used may not be
cost-effective for patients when they transition to the outpatient setting. Therapeutic
interchange may also limit patient choice in both the inpatient and outpatient settings.
In contrast, others argue that therapeutic interchange can be implemented safely while
enhancing efficiency. Interchanged medications are similar in effect and mechanism of
action, and their differences are often well-studied and well-known (31). Proponents
argue that these changes can be made safely as long as physicians are aware of potential
unintended consequences (31). A number of studies have shown that switching a
medication to one within the same class leads to equivalent outcomes for patients without
significant adverse or side effects (30,33,34,40,41). Furthermore, as the number of
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available drugs continues to rapidly expand, hospitals utilize therapeutic interchange as a
practical means of maintaining an efficient, high-quality formulary.
The debate regarding the relation of therapeutic interchange to patient care outcomes has
led to mixed conclusions. Studies of clinical consequences of therapeutic interchange
have been limited to the effect of single classes of medication on small numbers of
patients rather than the use of therapeutic interchange as a whole. For example, a study
looking at a policy change restricting the use of proton pump inhibitors to one preferred
drug showed no change in clinical complications or noncompliance (30). Other reports
have shown that exchanging statins or angiotensin receptor blockers leads to equivalent
clinical outcomes or improvement in lab values without significant adverse events
(33,40). In contrast, therapeutic interchange of proton pump inhibitors at another
institution correlated with lack of treatment response and increased side effects (42).
However, while therapeutic interchange may be controversial, its overall economic
benefit will continue to drive its existence.

Role of Therapeutic Interchange in Medication Errors
Despite substantial research on the cost-effectiveness and equivalency of therapeutic
interchange, the impact of this practice on patients’ medication regimens and medication
reconciliation errors has not been fully explored. Upon a patient’s admission to a
hospital, physicians often continue to prescribe the patient’s outpatient medications with
modifications as necessary, but hospital formularies frequently necessitate the
interchange of home medications for others—formulary medications—that the hospital
carries. These additional changes may increase the opportunity for medication errors.
During hospitalization, the modifications may increase risk of drug-drug interactions,
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side effects, or adverse effects. At discharge, when physicians perform medication
reconciliation to determine the patient’s new outpatient regimen, either the original or the
interchanged drug (or both or neither) may be selected, possibly leading to unintended
medication discrepancies (43). From the patient’s perspective, the changes may cause
confusion, and the patient may ultimately take both or neither medication after discharge.
Continuing the interchanged medication upon discharge may allow cost savings for the
patient with equivalent or better outcomes, or it may lead to increased prescription costs
and serious adverse drug effects.
Medication reconciliation errors made at admission, throughout hospitalization, and at
discharge have been well-investigated (18). However, though therapeutic interchange has
been implicated as a possible cause of medication reconciliation errors during hospital
stays (24), its contributory role has not been explicitly defined. Only one recent study by
Glaholt et al. (2014) has calculated the frequency at which therapeutic interchange
continues after discharge, but these were not further identified as intentional or
unintentional modifications. Given the pervasiveness of therapeutic interchange in
hospital settings and the many means in which it may negatively affect the patient,
further characterization of its effect on medication regimens in hospitalized patients is
warranted.
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Statement of Purpose
Hypothesis
Therapeutic interchange occurs frequently at the time of hospital admission and
contributes to prescriber error during hospitalization. The continuation of therapeutic
interchange upon discharge is uncommon, as patients are typically placed back on their
prior outpatient medications. However, the switching of medications via therapeutic
interchange contributes to medication reconciliation discrepancies at discharge.

Specific Aims
1. To evaluate the frequency and accuracy at which therapeutic interchange occurs at
hospital admission within a tertiary level healthcare system
2. To assess the extent to which therapeutic interchange continues at discharge into the
outpatient setting
3. To determine whether therapeutic interchange contributes to medication reconciliation
errors at discharge
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Methods
We conducted a retrospective chart review of data collected from a previous study. The
DIagnosing Systemic failures, Complexities and HARm in GEriatric discharges
(DISCHARGE) study was a prospective, observational cohort study of patients 65 years
or older admitted to Yale-New Haven Hospital for acute coronary syndrome, heart
failure, or pneumonia between May 2009 and April 2010 who were subsequently
discharged to home. Additional eligibility criteria included speaking English or Spanish,
not being in hospice care, and participating in a telephone interview; caregivers could
also take part on behalf of patients. Patients were excluded if they appeared delirious or
failed a mental status exam. The DISCHARGE study included an examination of
medication reconciliation accuracy and patient understanding of medication changes
post-discharge (24). The initial study was approved by the Yale Human Investigation
Committee.
During the time period of the study, the hospital used a combination of electronic health
records (Sunrise Clinical Manager 5.8 (Eclipsys Corporation, Atlanta, GA)) and paper
medical charts. The admitting physician recorded the admission medication list, or the
medications being taken upon arrival to hospital, in a paper or electronic note.
Medications prescribed during hospitalization were documented in handwritten or typed
progress notes, medication orders were entered electronically, and medications dispensed
were tracked by an electronic medication administration record (MAR). The discharging
physician used a prescription writer module to create the discharge medication list, which
automatically populated into the discharge instructions given to the patient. Clinicians
performed the medication reconciliations; pharmacists did not systematically review the
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final discharge list, and there was no active electronic medication reconciliation
technology.
In the current study, we examined the therapeutic interchange of six drug classes: proton
pump inhibitors (PPIs), histamine H2-receptor antagonists (H2 blockers),
hydroxymethylglutaryl CoA reductase inhibitors (statins), angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and inhaled
corticosteroids (ICS). We selected these drug classes based on their frequency of
therapeutic interchange, frequency of use, potential health impact in the event of
medication error, and large variances in cost within each drug class. The formulary
medications and their appropriate conversion dosages for the study institution during the
study period are listed in Table 1.
For the current study, the patient sample includes patients who were taking at least one
medication on admission that fell within the six drug classes listed above (referred to
henceforth as “medications of interest”). Admission and discharge medication lists were
previously abstracted but this work was repeated to check for accuracy; inpatient
medication lists were also abstracted. For each patient, we tracked medications of interest
from admission to hospital stay to discharge. Using the admission medication list as the
gold standard, we identified any therapeutic interchanges, change in dose or frequency,
suspension or discontinuation of medication, and addition of new medication that
occurred between admission and discharge.
The occurrence of therapeutic interchange was determined by comparing the admission
medication list to inpatient lists and the MAR. If a patient was placed on a formulary
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medication during hospitalization that was different from the home medication, but of the
same drug class, we considered that medication to be therapeutically interchanged. In
contrast, a home medication that was held or continued as the same medication
throughout hospitalization was not therapeutically interchanged.
Suspected medication errors include any medication discrepancies at admission or
discharge that did not appear intentional based on review of the medical record. The
scope of this study does not include the characterization of all medication reconciliation
errors at admission but rather focuses on suspected errors related to therapeutic
interchange. A correct therapeutic interchange requires that the physician accurately
converts the home medication—name, dose, and frequency—to the equivalent formulary
medication’s name, dose, and frequency. Using Table 1, we noted any inconsistencies in
the therapeutic interchange as suspected medication conversion errors at admission.
To identify discrepancies in medication reconciliation at discharge, we compared
discharge medication lists to their corresponding admission medication lists. Any
differences to the medications of interest between admission and discharge that did not
appear intentional were classified as suspected medication reconciliation errors at
discharge. We then examined whether therapeutic interchange at admission was
associated with these suspected errors at discharge.
We further characterized the medications of interest by whether they were changed to a
different drug (within the same drug class) or not at discharge and examined whether
therapeutic interchange at admission may be associated with these changes at discharge.
A drug change at discharge indicates that a patient admitted to the hospital on one
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medication was discharged to home on a different drug. A drug change may be
intentional, meaning it was clinically indicated or the result of modifications made during
hospitalization, or unintentional, meaning there was no apparent clinical indication and
thus was a suspected error.
The primary outcomes of this study included the percentage of medications of interest
that were therapeutically interchanged at admission and the frequency of suspected
conversion errors made during the interchange, as well as the percentage of medications
in which drug changes occurred at discharge and the rate of suspected medication
reconciliation errors associated with therapeutic interchange.
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Table 1: Formulary Conversions for Drug Classes of Interest
Table 1a: Formulary Conversions for ACE Inhibitors
FOR THE FOLLOWING ORDERS
benazepril
5mg QD

enalapril
----

fosinopril
5mg QD

INTERCHANGE USING

moexipril
3.75mg QD

perindopril
4mg QD

ramipril
1.25mg QD

trandolapril
0.5mg QD

quinapril
5mg QD

captopril
25mg QD

lisinopril

2.5mg QD

1mg QD

10mg QD

25mg BID

10mg QD

5mg QD

10mg QD

5mg BID

10mg QD

7.5mg QD

8mg QD
4mg BID

20mg QD
10mg BID

10mg BID*

20mg QD

15mg QD

----

5 mg QD

2mg QD

20mg QD (HTN)
20mg BID (CHF)

----

20mg BID

40mg QD

30mg QD

----

10mg QD

4mg QD

40mg QD

----

40mg QD

----

80mg QD

----

----

20mg QD

----

80mg QD

----

80mg QD

40mg QD
20mg BID
80mg QD

40mg BID

QD = daily, BID = twice daily, HTN = hypertension, CHF = congestive heart failure

Table 1b: Formulary Conversions for ARBs
FOR THE FOLLOWING ORDERS
candesartan
4mg QD
8mg QD
16mg QD
32mg QD

eprosartan
400mg QD
600mg QD

irbesartan
75mg QD
150mg QD

olmesartan
5mg QD
20mg QD

800mg QD

300mg QD

40mg QD

QD = daily, BID = twice daily

INTERCHANGE USING
telmisartan
---20mg QD
40mg QD
80mg QD

losartan
25mg QD
50mg QD
100mg QD

valsartan
40mg QD
80mg QD
160mg QD
320mg QD

20mg QD (HTN)
20mg BID (CHF)
*20mg QD (HTN and CHF)
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Table 1c: Formulary Conversions for H2 Blockers
FOR THE FOLLOWING ORDERS
CRCL (ml/min)
<50
>50

cimetidine
<30 ml/min: 300mg BID
<10ml/min: 300mg QD
300mg Q8H
400mg BID
800mg QD

nizatidine
150mg QD
150mg QOD
150mg BID
300mg QD

INTERCHANGE USING

ranitidine

famotidine

150mg QD

20mg QD

150mg BID

20mg BID

CRCL = creatinine clearance, QD = daily, QOD = every other day, BID = twice daily

Table 1d: Formulary Conversions for ICS
FOR THE FOLLOWING ORDERS
budesonide
90mcg 1 puff BID
180mcg 1 puff BID
180mcg 2 puffs BID

fluticasone
44mcg 1 puff BID
50mcg 1 puff BID
100mcg 1 puff BID
110mcg 2 puffs BID
220mcg 1 puff BID
110mcg 4 puffs BID
220mcg 2 puffs BID
250mcg 2 puffs BID

QD = daily, BID = twice daily

INTERCHANGE USING
beclomethasone

mometasone

40mcg 1 puff BID
80mcg 1 puff BID

220mcg 1 puff QD

80mcg 2 puffs BID

220mcg 1 puff BID
220mcg 2 puffs BID
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Table 1e: Formulary Conversions for PPIs
FOR THE FOLLOWING ORDERS
esomeprazole
20mg QD
40mg QD
40mg BID
60mg QD
60mg BID

dexlansoprazole
30mg QD
60mg QD

----

INTERCHANGE USING

lansoprazole
15mg QD
30mg QD

omeprazole
20mg QD
40mg QD

30mg BID
60mg QD
60mg BID

20mg BID
40mg BID
60mg QD
60mg BID

rabeprazole

pantoprazole

20mg QD

40mg QD

20mg BID
40mg BID
60mg QD
60mg BID
100mg QD

40mg BID

QD = daily, BID = twice daily

Table 1f: Formulary Conversions for Statins
FOR THE FOLLOWING ORDERS

INTERCHANGE USING*

fluvastatin
20mg QD
40mg QD
80mg QD
-------

lovastatin
10mg QD
20mg QD
40mg QD
80mg QD
----

simvastatin
5mg QD
10mg QD
20mg QD
40mg QD
80mg QD

atorvastatin
------10mg QD
20mg QD
40mg QD

----

----

----

80mg QD

rosuvastatin
---------5mg QD
10mg QD
20mg QD
40mg QD

pravastatin
10mg QD
20mg QD
40mg QD
80mg QD
-------

QD = daily. *Pravastatin was on formulary throughout study period (May 2009 – Apr 2010).
Atorvastatin was on formulary from May 2009 – Oct 2009. Rosuvastatin was on formulary
from Aug 2009 – Apr 2010
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Results
Study Sample
A total of 377 patients were enrolled in the DISCHARGE study, collectively taking 2,583
oral medications on admission. Of these, 303 (80.4%) patients were taking 555 (21.5%)
medications at admission that fell within the six drug classes of interest and were
included in this analysis (see Figure 1). The largest class of medications was statins,
which accounted for 41% of the medications of interest. On average, 49% of these
admission medications were non-formulary, or not carried by the formulary of the
hospital to which they were admitted; rates for individual classes ranged from 20% for
ACE inhibitors to 75% for PPIs (see Table 2).
Figure 1: Summary of Medications of Interest from Admission to Discharge
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Table 2: Medications of Interest Characterized by Drug Class and Formulary Status
Admission Meds
ACE inhibitor
ARB
H2 blocker
ICS
PPI
statin
Total

Non-formulary
25 (20%)
15 (25%)
14 (56%)
6 (60%)
84 (75%)
129 (57%)
273 (49%)

Formulary
97 (80%)
44 (75%)
11 (44%)
4 (40%)
28 (25%)
98 (43%)
282 (51%)

Suspected Medication Conversion Errors at Admission
Of the 555 medications, 244 (44.0%) were therapeutically interchanged to an approved
formulary drug at admission. This affected 64% (193 of 303) of the study patients who
had at least one medication of interest interchanged at admission. The remaining
medications which were not therapeutically interchanged were either continued
unchanged as the same drug or were held for the duration of the hospital stay (Table 3).
Table 3: Classification of Medication Modifications During Hospitalization
Admission Meds
TI
Unchanged
Held
11%
63%
25%
ACE inhibitor
19%
54%
27%
ARB
36%
48%
16%
H2 blocker
50%
10%
10%
ICS
53%
23%
24%
PPI
64%
30%
5%
statin
Total
44%
40%
16%
TI = therapeutic interchange, unchanged = admission medication
given during hospitalization, held = medication not given
throughout hospitalization

Among the therapeutically interchanged drugs, we identified 78 (32.0%) suspected
medication conversion errors, affecting 77 different patients, which resulted in the patient
receiving incorrect treatment in hospital (Fig. 1). Most of the suspected conversion errors
involved statins (79.2%). For example, one patient taking simvastatin 40mg daily prior to
admission was placed on pravastatin 40mg daily while inpatient instead of the correct
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interchange of pravastatin 80mg daily. Of the 78 suspected dose conversion errors made
at admission, the same potential error was carried forward to the discharge medication list
in 3 (3.8%) instances.

Suspected Medication Reconciliation Errors at Discharge
We identified potential medication reconciliation errors at discharge involving 41 (7.4%)
of the 555 medications of interest (Fig 1). 28 of these were medications that had been
therapeutically interchanged during admission. This corresponds to a suspected error rate
of 11.5% (28 of 244) among therapeutically interchanged medications compared to 4.2%
(13 of 311) among unaffected medications; suspected medication reconciliation errors
were significantly more likely to occur among medications that had been therapeutically
interchanged than those that had not been (RR 2.75, 95% CI 1.45-5.19).
The most common form of suspected medication reconciliation error at discharge
involved unindicated changes to medication type, with or without additional errors in
dosage or frequency (first two rows in Table 4). Omission of a medication was also
frequent; other suspected errors included duplication, inadvertent continuation, or
incorrect dosing changes.

Drug Changes at Discharge
36 (6.5%) of the 555 medications of interest were changed at discharge to a different
medication within the same drug class as the patient’s original admission medication (Fig
1). The regimen change occurred in 28 of the 244 therapeutically interchanged
medications (11.5%) as compared to 8 of the 311 non-therapeutically interchanged drugs
(2.6%), indicating a statistically significant difference (relative risk (RR) 4.46, 95%
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confidence interval (CI) 2.07-9.61). In 39% of total cases, these drug changes appeared
intentional as consequences of inpatient management; for example, a patient admitted on
esomeprazole was switched to a therapeutically equivalent dose of the formulary drug
pantoprazole, but because of GI symptoms, the frequency of pantoprazole administration
was increased, and she was discharged on this new regimen. For the majority of drug
changes, however, the replacement appeared unintended and was classified not only as a
drug change but also as a suspected medication reconciliation error at discharge.
Table 4: Suspected Medication Reconciliation Errors at Discharge Characterized by Type
Type of Suspected Error at Discharge

TI

No TI

10

2

5

3

Two medications in same drug class prescribed

3

1

Admission medication discontinued without clear
indication; no equivalent medication prescribed

6

4

Dose of admission medication incorrect

2

2

1

0

1

1

28

13

Different medication in same drug class as
admission medication prescribed, equivalent in
dose/frequency, without clear indication
Different medication in same drug class as
admission medication prescribed, not equivalent
in dose/frequency, without clear indication

Admission medication continued when intended
to be stopped
Admission medication prescribed when intended
to change to different medication
Total

TI = therapeutic interchange occurred at admission, No TI = therapeutic
interchange did not occur—admission medication unchanged or held
during hospitalization
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Discussion
Our study found that, within six commonly used drug classes, close to half of
medications were therapeutically interchanged at admission, and errors occurred in onethird of these conversions. Furthermore, therapeutic interchange led to 2.75 times more
suspected medication reconciliation errors and 4.5 times as many changes in drug type at
discharge. Together, these results indicate that therapeutic interchange is a common
process that affects patients’ medication regimens from admission to beyond discharge,
and suggest that therapeutic interchange may be a key contributor to medication
reconciliation errors.
This study was limited to six classes of medications; however, of all eligible patients
included in the original DISCHARGE study, 80.4% of patients were taking at least one
medication in these six classes, making our study highly generalizable. 64% of included
patients experienced at least one therapeutic interchange during hospitalization,
suggesting the importance of thorough evaluation of the effects that therapeutic
interchange has on medication regimens and errors.
Previous studies characterizing medication errors made at time of hospital admission do
not include errors related to therapeutic interchange. Typically, such investigations focus
on discrepancies made between the admission medication list and patients’ actual
outpatient regimen when constructing the best possible medication history, but do not
explore therapeutic interchange as the next step of the transition process. Thus, the
discovery of a 32% suspected error rate in the implementation of therapeutic interchange
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is a novel finding. Given the high rate of the possible interchange errors, more attention
should be placed on addressing this aspect of patient care around the time of admission.
These suspected conversion errors suggest that therapeutic equivalence was not achieved
during hospitalization. This creates an opportunity for adverse drug events and
complications in inpatient care to arise. Potential adverse events may be exacerbated by
the fact that patients are likely to be unaware of the changes in medication and do not
have the means to verify their inpatient regimen for dosing accuracy, as illustrated in a
study which found that 36% of patients subject to PPI therapeutic interchange during
hospitalization were unaware that a substitution had occurred (44). Prior studies
demonstrate that 27-40% of admission medication discrepancies have the potential to
cause harm during hospitalization, and as they do not include the role of therapeutic
interchange, the potential for harm may be significantly higher (13,18,19).
Suspected conversion errors at admission may also have potential for harm beyond
hospitalization if they are not remedied at discharge. In this study, 3 of the 78 (3.8%)
suspected conversion errors were continued at discharge such that the patient may have
continued the incorrect therapeutic interchange at home. This occurred far less frequently
than the one-third of admission discrepancies observed by Pippins and colleagues,
although that included all unintentional medication discrepancies rather than only ones
related to therapeutic interchange (18).
At the time of discharge, suspected medication reconciliation errors were identified in
7.4% of medications analyzed, affecting 12.5% of the patients involved. This rate is
comparable to other studies, although this study was far reaching than most by including
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errors of omission, duplication, changes in dosage and frequency, inadvertent
continuations and therapeutic interchange (24). Again, while other types of medication
errors at discharge have been previously described, discrepancies related to therapeutic
interchange have thus far not been specifically examined. Suspected errors were almost
three times more likely to occur in medications that were interchanged during
hospitalization; many of these suspected errors involved medications that were not
reverted back to the home regimen, and were likely a direct consequence of therapeutic
interchange. The potential for error after discharge is high, as patients may take the
incorrect dosage of a medication, take two medications of the same class, or discontinue
an essential treatment.
Furthermore, we found that in 6.5% of cases, a patient’s admission medication changed
to a different drug of the same class at discharge. Such changes in medication regimen,
whether clinically indicated or not, affected 13% of patients who underwent at least one
therapeutic interchange. This coincides with the 2014 findings of Glaholt et al. who
observed that 15% of adult patients admitted to an academic medical center who
experienced therapeutic interchange were not restarted on their original outpatient
therapy. Medication switches were significantly more likely to occur to medications that
were changed for formulary reasons than for medications that were unchanged or held
during hospitalization.
Minimizing changes to drug regimens, especially in vulnerable populations such as the
elderly in this study, is important in avoiding patient misunderstanding and potential
adverse drug effects. Alterations are problematic because patients may have a previous
home supply available but be required to obtain a new prescription for a therapeutically
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equivalent drug following discharge. Subsequent confusion may increase the likelihood
of medication duplication or omission, possibly putting the patient at risk for drug-drug
interactions, side effects, and adverse reactions. For these reasons, physicians should
make changes from one medication to another carefully and only when indicated, and be
aware of potential unintentional consequences.
Our study shows that therapeutic interchange is a common practice that likely contributes
to medication errors at admission and discharge. Given this, healthcare providers must
give appropriate attention to therapeutic interchange during all aspects of hospitalization,
and physicians must be careful when making medication modifications due to formulary
restrictions rather than clinical indication. Aside from provider awareness, we may be
able to reduce errors related to therapeutic interchange by instituting systems-level
changes to hospitals. For example, just as standardized protocols can improve medication
reconciliation, the use of formalized tools likely can make therapeutic interchange safer.
Medication reconciliation protocols should indicate which medications undergo
therapeutic interchange at admission and include a means of ensuring that this
interchange is reversed at discharge. Formulary conversion charts such as Table 1 should
be readily accessible to promote accurate changes. Another potential method of
improvement is to include pharmacists in the medication reconciliation process. In
comparison to physicians and other providers, pharmacists are especially suited to this
responsibility because of their training, but they also are extremely familiar with their
hospital’s formulary, which may specifically reduce therapeutic interchange errors
(17,20,45). The use of an active electronic medication reconciliation system that can flag
therapeutic interchanges may also aid providers (46). Finally, further studies of the use of
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therapeutic interchange, reasons for associated errors, and potential adverse events during
and after hospitalization should be performed to better elucidate the impact of therapeutic
interchange on patient care.

Limitations
There are several limitations to this study. First, as a retrospective chart review, the
admission medication list documented in the patient charts was treated as the gold
standard although, as discussed above, numerous studies have shown high rates of
medication reconciliation errors at admission. Furthermore, we could not verify
intentional changes or suspected errors to regimens at admission or discharge with the
patients’ actual providers. Third, the study is limited to patients from a single tertiary
level hospital in an urban area and may not be generalizable to practices at other
hospitals. Limiting the investigation to six drug classes rather than all medications may
affect rates of therapeutic interchange and suspected errors.

Conclusion
Therapeutic interchange is highly prevalent in the hospital setting but markedly elevates
the risk for potential medication errors during and after hospitalization. The benefits of
therapeutic interchange should be carefully weighed against the potential for increased
errors and adverse events.
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